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Converging
technologies: targeting
the hallmarks of cancer
using ultrasound and
microbubbles
Janith Wanigasekara, 1,2,3,6
Andressa Maria Aguiar
de Carvalho, 1,2,3,6
Patrick J. Cullen, 1,4
Brijesh Tiwari, 2 and
James F. Curtin 1,3,5,*

Various complex biological effects
occur when ultrasonic compression
waves travel through biological
material. The myriad of biological
outcomes instigated by ultrasound
are evident when viewed through
the lens of the hallmarks of cancer.
Herein, we summarise the therapeutic potential of ultrasound,
enhanced by microbubbles, for the
treatment of cancer.

Biological effects of ultrasound
The hallmarks of cancer are a useful
framework to distil and understand the underlying changes in this incredibly complex
and diverse disease [1]. Six core and two
emergent hallmarks underpin tumour development and metastasis. Two enabling
hallmarks provide ‘functional capabilities
that allow cancer cells to survive, proliferate, and disseminate’ (Figure 1). Drug
development primarily focusses on singular receptors, whereas each hallmark is
regulated by semi-redundant pathways
allowing tumour adaptation and chemoresistance via mutation [1]. Therapies that
broadly target hallmarks of cancer are
therefore advantageous to prevent tumour
adaptation. Ultrasound imparts focussed
energy via ultrasonic compression waves
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directly to cells and tissues. When used in
combination with gas-ﬁlled microbubbles,
the resultant microbubble oscillation,
expansion and contraction, and bursting
enhances the antitumour effects of ultrasound, broadly targeting several hallmarks
of cancer. Here, we propose that ultrasound therapies can be codiﬁed within the
hallmarks of cancer framework.

Resisting cell death
Many existing chemotherapies target
receptors with the therapeutic intent to
overcome or bypass inherent tumour resistance to cell death. Direct application
of ultrasound can overcome resistance
to cell death, inducing coagulative necrosis, apoptosis, and reduction of tumour
growth [2]. However, in glioblastoma and
other brain tumours, the blood–brain barrier (BBB) prevents many chemotherapeutic agents from accumulating to effective
concentrations in tumours. Two clinical
trials used minimally invasive ultrasound to
temporarily and repeatedly open the BBB
and enhance chemotherapeutic delivery
without adverse effects [3,4]. A Phase I/II
clinical trial (NCT02253212) enhanced
carboplatin uptake without evident neurotoxicity using the implantable ultrasound device, sonocloud-1, combined
with microbubbles [3], and a second
Phase I trial (NCT02343991) effectively
delivered doxorubicin- and temozolomideloaded liposomes using low-intensity magnetic resonance (MR)-guided focussed
ultrasound [4]. These approaches demonstrate the in-human feasibility of micro/
nano bubbles and ultrasound to enhance
drug delivery, improve penetration and
bioavailability in the brain parenchyma,
increase local intracerebral drug concentrations, while reducing systemic toxicology.
Preclinical development of a sonodynamic
therapy complex incorporating chlorin e6
and hydroxychloroquite into liposomes
illustrates this point. The complex selectively accumulated in brain tumours during
ultrasound-targeted microbubble destruction and hydroxychloroquine was released

to glioma cells, inducing reactive oxygen
species (ROS) production, mitochondrial
dysfunction, and MAPK/p38-PINK1-PRKNdependent mitophagy [5].
Microbubbles and gene-loaded nanoparticles combined with ultrasound also
provides a safe, effective, and targeted
delivery system for genes. Microbubbles
and a lipid-polymer hybrid nanoparticle
complex were used as an ultrasoundmediated gene delivery carrier of clustered
regularly interspaced short palindromic
repeats (CRISPR)-Cas9 plasmids, targeting
O6-methylguanine-DNA methyltransferase
(MGMT), a DNA-repair gene protecting
glioma cells from alkylating chemotherapeutics. Ultrasound induced BBB opening,
allowing targeted delivery, gene protection
from enzyme degradation, biocompatibility,
prolonged survival, biosafety, and augmented transfection efﬁciency, while downregulating MGMT expression and thereby
sensitising cells to temozolomide [6].
Microbubbles loaded with the halogenated xanthene contrast agent rose bengal conjugated via stable amine linkages
to dihexadecylamine combined with ultrasound has been used as a novel
sonosensitiser delivery system in a preclinical in vivo study. Ultrasound converted
loaded microbubbles into nanoparticles,
resulting in enhanced drug accumulation
in the tumour and ROS generation, leading
to tumour growth inhibition with minimal
side effects [7]. Ultimately, microbubbles
combined with ultrasound can overcome
cell death resistance. Future progress will
be dependent on further development of
materials that increase tumour cell death
while minimising damage to surrounding
cells. While not yet undergoing clinical trials, nanomaterials combined with ultrasound have potential to selectively ablate
tumour tissue deep within the body.

Sustaining cell proliferation
Cancer cells deregulate the normal signals
that control entry and progression through
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Figure 1. Ultrasound targets the hallmarks of cancer. Ultrasound directly modulates ﬁve core hallmarks and one emerging hallmark of cancer. Figure created with
BioRender. Abbreviations: I, core hallmarks; II, enabling hallmarks; III, emerging hallmarks; ROS, reactive oxygen species; TP53, tumour protein P53.

the cell cycle, resulting in sustained cell
proliferation. Antineoplastic agents have
been developed, such as gemcitabine,
to inhibit DNA synthesis in cancer cells.
Moreover, high expression of some
miRNAs, such as miR-21, has been
shown to downregulate tumour suppressors and modulate Akt phosphorylation and others, such as miR-122,
have tumour suppressor effects and
are downregulated in various cancers,
suggesting that targeting miRNAs could
inhibit cancer cell proliferation. Ultrasoundtargeted microbubble destruction can
enhance clathrin-mediated endocytosis of
nanoparticles and therefore enhance delivery of antineoplastic agents. A preclinical

pancreatic cell study using ultrasoundtargeted microbubble disruption promoted
uptake of dendrimer-entrapped gold
nanoparticles loaded with gemcitabine
or a miR-21 antisense inhibitor, increasing cytotoxicity by more than 80-fold
and 10-fold, respectively. This approach
reduced tumour volume and increased
blood perfusion in vivo [8]. Similar effects
were seen in hepatocellular carcinoma
(HCC) when sense miR-122 and antisense anti-miR-21 were encapsulated
into poly (lactic-co-glycolic acid) nanoparticles and delivered by ultrasoundmediated microbubble disruption. This
approach induced dose-dependent decreases of antiapoptotic proteins CD-320

and IGFR-1 and dose-dependent increase
of the proapoptotic protein Programmed
Cell Death Protein 4, along with enhanced
HCC death in doxorubicin-resistant and
nonresistant human xenografts in vivo [9].
In a Phase I clinical trial (NCT01674556),
ultrasound combined with microbubbles
and gemcitabine was demonstrated to be
clinically feasible and safe, while enhancing
intratumoural drug delivery. This combination treatment also doubled median survival of patients with inoperable pancreatic
cancer [10].
Epidermal growth factor receptor (EGFR)
also promotes cell proliferation and is
commonly overexpressed in cancers.
Trends in Cancer, October 2021, Vol. 7, No. 10
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Permeabilization of intact BBB using ultrasound in combination with microbubbles was applied before injecting
89
Zr-labeled anti-EGFR monoclonal antibody (cetuximab). This allowed prolonged
exposure of the brain parenchyma to
cetuximab with slow diffusion and clearance, allowing for high and localised exposure to monoclonal antibodies [11].

Inducing angiogenesis
Angiogenesis is required to sustain tumour
growth and much effort has been devoted
to inhibiting blood vessel growth to reduce
tumour burden. Ultrasound inhibits tumour
neovascularisation, inducing thrombosis
and preventing metastasis. Moreover,
heat caused by microbubble oscillation
results in selective damage in tumour endothelial cell linings due to slower blood
ﬂow and a higher retention of microbubbles
in the tumour neovasculature. This effect
leads to inhibition of tumour neovascularisation and potentially necrosis, apoptosis,
reduced tumour growth, and improved
survival [12]. We expect to see a future
shift away from microbubbles towards
nanobubbles that damage tumour endothelial cell linings more effectively.

Tissue invasion and metastasis
Invasion and metastasis are commonly
associated with poor tumour prognosis.
Tumour cells leave the primary tumour
site and enter the vascular system before
forming distal metastases. MET activation
is involved in epithelial to mesenchymal
transformation, which is necessary for invasion and metastasis. Ultrasound induces
gas accumulation within cell membranes,
altering cell membrane micro-morphology,
thereby interrupting MET-induced cell
motility [13].
Additional efforts are underway to target
tumour cells from entering the bloodstream or inhibiting blood vessel cells
from allowing cells to pass through.
Microbubbles can cause capillary damage, activating coagulation and inducing
888
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thrombosis, thereby limiting or preventing
metastasis [12]. Moreover, as EGFR is
also involved in cell migration, the combination of cetuximab with ultrasound and
microbubbles increases permeability of
cetuximab into the brain, thereby leading
to reduced migration in a preclinical study
[11]. While promising preclinical results
have been demonstrated, clinical effects
of ultrasound on invasion and metastasis
remain unclear and further exploration will
allow a more complete understanding of
whether ultrasound can inhibit this hallmark.

Evading immune destruction
Evasion of the immune system and defective or suppressed immune responses
against tumour antigen are common features of cancer. These immune responses
can be (re)activated under certain conditions, making them an ideal target to ﬁght
cancer more effectively. Recent efforts to
counter tumour-induced immune suppression has led to the development of
various immune-based therapies, including immune checkpoint inhibitors and
adoptive cellular therapies. The feasibility
of ultrasound-triggered transfection of
bone marrow-derived dendritic cells
(BM-DC) was demonstrated in preclinical
models. Primary murine C57BL/6 BM-DC
cultures were generated and ultrasoundtriggered transfection of BM-DC cultures
was achieved using microbubbles loaded
with both antigen (OVA257-264 SIINFEKL)
mRNA as well as immunomodulating TriMix
mRNA. This enabled potent OVA257-264
antigen-speciﬁc immune responses in vivo
against MO4 melanoma cells and E.G7OVA T lymphoma cells, resulting in a significant reduction of tumour growth, increased
survival, and long-lasting antigen-speciﬁc
protection against tumour recurrence [14].
By releasing damage-associated molecular
patterns (DAMPs), increasing immune cell
inﬁltration, decreasing immunosuppressive
cytokine release from tumour cells, and releasing cell debris, including tumour antigen
through the above-mentioned mechanisms
[2], the potential for ultrasound to augment

immune responses is clear. Further studies
should evaluate the combination of ultrasound with immune-based therapies.

Deregulated metabolism
Cancer cells adapt their metabolism to
support biomass production, ATP generation, and maintain redox state. Disrupting
these processes can interfere with tumour
growth and metastasis. Ultrasound enhances endocytosis and exocytosis, thereby
modifying nutrient, micronutrient, and ion
uptake [15] and, potentially, cancer cell
metabolism. Ultrasound induces cavitation, enhancing cell and tissue membrane
permeability, and creates free radicals.
Direct biological effects and bystander
effects of cavitation and free radical production can be further enhanced using
microbubbles and sonosensitisers and
controlled by adjusting duration, amplitude, intensity, frequency, shape, focus,
and type of ultrasound transducer used
[2,12].

Concluding remarks
Ultrasound elicits a range of biological
changes in a tumour with minimally invasive technology. Clinical trials demonstrate
safe delivery of a range of therapeutic
agents across the BBB and into cancer
cells, along with in situ heat-dependent
cytotoxicity to the tumour. Advances in
microbubble and nanobubble technologies will further improve combinational
therapy approaches. A wide array of clinical trials are planned or underway using
chemotherapy, sonodynamic therapy,
immunotherapy, and overcoming BBB,
many incorporating microbubbles or
nanomaterials. However, there are no reported clinical trials currently planned or
underway using ultrasound and microbubbles to enhance gene delivery, despite
successful preclinical studies, including the
above-mentioned CRISPR-Cas9 studies
[6], miRNA studies [8,9], and BM-DC transfection studies [14]. These ﬁndings demonstrate the potential of nucleic acid delivery
by ultrasound and microbubbles and as
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Table 1. Clinical trials combining ultrasound and microbubbles/nanomaterials
Ultrasound device

Combination

Condition/disease

Phase

Hallmarka

Status

Identiﬁer
(NCT number)

Chemotherapy
Focused ultrasound

Contrast-enhanced
ultrasound

Magnetic
resonance-guided
high-intensity
focused ultrasound

Lyso-thermosensitive liposomal doxorubicin

Liver tumour

I

I

Completed

NCT02181075 [16]

FOLFIRINOX regime, microbubbles

Pancreatic ductal
adenocarcinoma

II

I

Recruiting

NCT04146441

Panobinostat, microbubbles

Diffuse intrinsic
pontine glioma

I

I

Recruiting

NCT04804709

Conventional chemotherapy, microbubbles
containing sulphur hexaﬂuoride stabilised by
phospholipids

Colorectal
neoplasms,
breast neoplasms

I/II

I

Recruiting

NCT03477019

Platinum, gemcitabine, microbubbles

Gastrointestinal
neoplasms

I/II

I

Recruiting

NCT02233205

Gemcitabine hydrochloride, nab-paclitaxel,
ﬂuorouracil, irinotecan hydrochloride, leucovorin
calcium, oxaliplatin, perﬂubutane microbubble

Metastatic
pancreatic ductal
adenocarcinoma

I/II

I

Not yet
recruiting

NCT04821284

Perﬂutren protein-type A microspheres,
microbubble

Hepatocellular
carcinoma

II

I

Recruiting

NCT03199274

Gaseous microbubbles, systemic chemotherapy,
sonoporation

Liver metastases of
colorectal cancer

II

I

Recruiting

NCT03458975

Neoadjuvant chemotherapy, sulphur hexaﬂuoride
microbubbles

Breast cancer

N/A

I

Completed
(no results
posted)

NCT00245869

Gemcitabine, microbubbles

Pancreatic
adenocarcinoma

I

I

Completed

NCT01674556 [10]

Lyso-thermosensitive liposomal doxorubicin,
cyclophosphamide

Metastatic breast
cancer

I

I

Recruiting

NCT03749850

Lyso-thermosensitive liposomal doxorubicin

Refractory solid
tumours

II

I

Not yet
recruiting

NCT04791228

Lyso-thermosensitive liposomal doxorubicin

Paediatric cancer

I

I

Recruiting

NCT02536183

N/A

Recurrent
glioblastoma

N/A

I

Completed
(no results
posted)

NCT03626896

Bevacizumab, microbubbles

Recurrent
glioblastoma

N/A

I

Recruiting

NCT04446416

Carboplatin

Recurrent
glioblastoma

I/II

I

Recruiting

NCT04440358

Microbubbles

Brain tumour

N/A

I

Active, not
recruiting

NCT02343991 [4]

Carboplatin

Recurrent
glioblastoma

I/II

I

Recruiting

NCT04417088

N/A

Brain metastases
of breast cancer

N/A

I

Recruiting

NCT03714243

Temozolomide

Glioblastoma

N/A

I

Recruiting

NCT03712293

Blood–brain barrier disruption
NaviFUS system

ExABlate system

SonoCloud-9
system

Albumin-bound paclitaxel, microbubbles

Glioblastoma

I/II

I

Recruiting

NCT04528680

Carboplatin

Recurrent
glioblastoma

I/II

I

Completed

NCT02253212 [3]

Carboplatin

Recurrent
glioblastoma

1/2

I

Active, not
recruiting

NCT03744026

Nivolumab injection

Brain metastases
of melanoma

1/2

I

Recruiting

NCT04021420
(continued on next page)
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Table 1. (continued)
Ultrasound device
Focused ultrasound

Combination

Condition/disease

Phase

Hallmarka

Status

Identiﬁer
(NCT number)

N/A

Glioblastoma

N/A

I

Recruiting

NCT03616860

N/A

Glioblastoma

N/A

I

Recruiting

NCT03551249

Focused ultrasound
ablation (Echopulse)

PD-1 antibody blockade

Advanced solid
tumours

I

III

Recruiting

NCT04116320

High-intensity
focused ultrasound

PD-1 antibody blockade (pembrolizumab)

Metastatic breast
cancer

I

III

Recruiting

NCT03237572

Low-intensity pulsed
ultrasound
(SONOCLOUD)

PD-1 antibody blockade (nivolumab and
pembrolizumab)

Brain metastases
of melanoma

I/II

I

Recruiting

NCT04021420

SONALA-001(5-aminolevulinic acid)

High grade
glioma

I

I

Recruiting

NCT04559685

5-Aminolevulinic acid

Glioblastoma

N/A

II

Not yet
recruiting

NCT04845919

Immune therapy

Sonodynamic therapy
Magnetic
resonance-guided
high-intensity
focused ultrasound
a

Abbreviations: I, core hallmarks; II, enabling hallmarks; III, emerging hallmarks; N/A, not applicable.

a clinical research gap worth exploring
(Table 1).
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